📢 Join us at @IP_London We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04) 🔗 www.imperial.ac.uk/jobs/search-... @londonprostate1.bsky.social @connorurol.bsky.social

Thank you to @thetimes.com 📰for covering my first major grant success - the £1.89M #IP13AVIDITY randomised trial testing PSMA PET defined and escalated treatment compared to standard of care for high-risk #prostatecancer @prostateukprofs.bsky.social www.thetimes.com/uk/healthcar...

Great presentation from our PhD fellow Archana 👏🥇 at the RSM London showing the possibilities of immediate bladder pathology at time of TURBT using the Histolog FCM scanner! @archanagk.bsky.social @ip-london.bsky.social #RSMUrology #LaserComplete #TheUrologyFoundation

Working link to full open access article here: www.bmj.com/content/387/...

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

It was a record meeting for Imperial Prostate at #BAUSOncology 2024 with presentations on prostate cancer screening, early detection, molecular imaging and discussion of many of our ongoing/upcoming trials from our fellows, lecturers, and consultants #ATLAS #AVIDITY #FLUORESCE #PACIFIC #TRANSFORM